| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Naylor Dana Institute for Disease Prevention, American Health Foundation, Valhalla, New York 10595
The tumorigenic activities and DNA methylating abilities in F344 rats of the tobacco specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and the structurally related nitrosamine N-nitrosodimethylamine (NDMA) were compared. Groups of 30 male rats were given 60 s.c. injections of 0.0055 mmol/kg of either NNK or NDMA over a 20-week period (total dose, 0.33 mmol/kg). The experiment was terminated after 104 weeks. The numbers of rats with tumors were as follows for NNK and NDMA, respectively: liver, 10 and 6; lung 13 and 0; and nasal cavity, 6 and 1. NNK was significantly more tumorigenic than was NDMA toward the lung (P < 0.01) and nasal cavity (P < 0.05). Groups of rats were treated with a single s.c. injection of 0.39 mmol/kg or 0.055 mmol/kg of NNK or NDMA and the levels of 7-methylguanine and O6-methylguanine were measured in liver, lung, and nasal mucosa 148 h after treatment. In liver and lung, levels of 7-methylguanine and O6-methylguanine in DNA were 322 times (P < 0.001) greater in NDMA treated rats than in NNK treated rats. Levels of methylation induced by NDMA and NNK in the nasal mucosa were similar. The results of this study demonstrate that NNK is a more potent tumorigen than NDMA in the F344 rat and suggest that DNA methylation alone does not account for its strong tumorigenicity in rat lung and nasal mucosa.
1 Supported by National Cancer Institute Grant CA-21393. This is Paper 88 in "A Study of Chemical Carcinogenesis."
2 To whom requests for reprints should be addressed.
Received 7/25/85. Revised 10/16/85. Accepted 10/28/85.
This article has been cited by other articles:
![]() |
L. E. Sandercock, J. N. Hahn, L. Li, H.A. Luchman, J. L. Giesbrecht, L. A. Peterson, and F. R. Jirik Mgmt deficiency alters the in vivo mutational spectrum of tissues exposed to the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) Carcinogenesis, April 1, 2008; 29(4): 866 - 874. [Abstract] [Full Text] [PDF] |
||||
![]() |
R.D.C. Barley, S. Pollock, M.C. Shallow, E. Peters, and E.W.N. Lam Tobacco-related-compound-induced Nitrosative Stress Injury in the Hamster Cheek Pouch J. Dent. Res., December 1, 2004; 83(12): 903 - 908. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Peterson, N. M. Thomson, D. L. Crankshaw, E. E. Donaldson, and P. J. Kenney Interactions between Methylating and Pyridyloxobutylating Agents in A/J Mouse Lungs: Implications for 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced Lung Tumorigenesis Cancer Res., August 1, 2001; 61(15): 5757 - 5763. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. C. Pulling, D. M. Klinge, and S. A. Belinsky p16INK4a and {beta}-catenin alterations in rat liver tumors induced by NNK Carcinogenesis, March 1, 2001; 22(3): 461 - 466. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Zhang, D. L. Weddle, P. E. Thomas, B. Zheng, A. Castonguay, H. M. Schuller, and M. S. Miller Low Levels of Expression of Cytochromes P-450 in Normal and Cancerous Fetal Pancreatic Tissues of Hamsters Treated with NNK and/or Ethanol Toxicol. Sci., August 1, 2000; 56(2): 313 - 323. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Schrader, K. I. Hirsch-Ernst, E. Scholz, G. F. Kahl, and H. Foth Metabolism of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in Primary Cultures of Rat Alveolar Type II Cells Drug Metab. Dispos., February 1, 2000; 28(2): 180 - 185. [Abstract] [Full Text] |
||||
![]() |
L. Liu, X. Qin, and S. L. Gerson Reduced lung tumorigenesis in human methylguanine DNA—methyltransferase transgenic mice achieved by expression of transgene within the target cell Carcinogenesis, February 1, 1999; 20(2): 279 - 284. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Mitacek, K. D. Brunnemann, D. Hoffmann, T. Limsila, M. Suttajit, N. Martin, and L. S. Caplan Volatile nitrosamines and tobacco-specific nitrosamines in the smoke of Thai cigarettes: a risk factor for lung cancer and a suspected risk factor for liver cancer in Thailand Carcinogenesis, January 1, 1999; 20(1): 133 - 137. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. E. Gram Chemically Reactive Intermediates and Pulmonary Xenobiotic Toxicity Pharmacol. Rev., December 1, 1997; 49(4): 297 - 342. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Code, C. L. Crespi, B. W. Penman, F. J. Gonzalez, T. K. H. Chang, and D. J. Waxman Human Cytochrome P4502B6. Interindividual Hepatic Expression, Substrate Specificity, and Role in Procarcinogen Activation Drug Metab. Dispos., August 1, 1997; 25(8): 985 - 993. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |